Ownership history in Rubric Capital Management LP Β· 30 quarters on record
This page tracks every 13F SEC filing in which Rubric Capital Management LP reported a position in THERAPEUTICSMD INC (TXMD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Rubric Capital Management LP underperformed the S&P 500 by β34.8% annually on this TXMD position. Timing score: 33% (5/15 decisions correct). Average cost basis: $112.08. Maximum drawdown during holding period: β99.6%.
β Significantly underperformed the S&P 500 by 34.8% ann.
11 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
5 of 15 add/trim decisions correct
Best entry: $5.59 (2022 Q4) Β· Worst: $243.50 (2019 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
8 adds Β· 7 trims. Bought during 4 of 16 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.02% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size